IP Library Granted Patent US 10,112,904
Granted Patent B2
US 10,112,904 · App. 15/503,686 · Granted Oct 30, 2018

Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Inventors: John Ford (Cambridgeshire, GB); Johannes Paulus Gerardus Seerden (MC Gronningen, NL); Amandine Ledru (Belfast, GB)
Assignee: DEZIMA PHARMA B.V.
C07D215/42C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,112,904
App. No.
15/503,686
Granted
Oct 30, 2018
Kind
B2
Abstract

The present invention relates to a process for the preparation of synthetic intermediates which may be used in the preparation of tetrahydroquinoline derivatives, which derivatives have an inhibitory activity against cholesteryl transfer protein (CETP), show effects of increasing HDL cholesterol level and decreasing LDL cholesterol level, and can be used for the treatment and/or prevention of diseases such as arteriosclerotic diseases, hyperlipidemia, dyslipidemia and the like.

Claims (25)

1. A process for preparing the racemic compound of formula I or a salt thereof:

comprising the steps of:

(a) simultaneously reacting 4-aminobenzotrifluoride according to formula II

with an aldehyde according to formula III

and with a compound according to formula IV

in the presence of a solvent and optionally one or more catalysts to form the compound of formula V

wherein

R 1 is H or C 1 -C 3 alkyl;

R 2 is H, C 1 -C 3 alkyl or

(b) hydrolyzing the compound of formula V to form the compound of formula (I); wherein prior to step (b) the compound of formula V is separated from the reaction mixture of step (a).

2. The process according to claim 1 , wherein R 1 is CH 2 CH 3 and R 2 is H.

3. The process according to claim 1 , wherein the solvent used is dichloromethane, acetonitrile, ethyl acetate, toluene or a mixture thereof.

4. The process according to claim 1 , wherein the catalyst used in step a) is an acid, comprising a Brønsted acid or a Lewis acid.

5. The process according to claim 4 , wherein the catalyst is 4-toluenesulfonic acid.

6. The process according to claim 1 , wherein the compound of formula V is separated from the reaction mixture of step (a) by precipitation from the reaction mixture by means of the addition of a non-polar solvent to said reaction mixture.

7. The process according to claim 6 , wherein the non-polar solvent is a heptane, cyclohexane or a mixture thereof.

8. The process according to claim 1 , wherein in step (b) the compound of formula V is hydrolyzed by warming a mixture comprising said compound for 1 hour to 3 hours at a temperature of 45° C. to 80° C. in the presence of an aqueous acid or in the presence of an alcohol and an aqueous acid.

9. The process according to claim 8 , wherein the acid is hydrochloric acid.

10. The process according to claim 8 , wherein the alcohol is ethanol.

11. The process according to claim 1 , further comprising a step c) wherein the 2R,4S-enantiomer of the racemic compound of formula I having a molecular formula according to formula I-a

wherein, R 1 is H or C 1 -C 3 alkyl, is separated from said compound of formula I.

12. The process according to claim 11 , wherein the separation of the enantiomer according to formula I-a is carried out by means of resolution with a chiral resolving agent, such as L-tartaric acid or a derivative thereof, such as di-p-toluoyl-L-tartaric acid.

13. The process according to claim 11 wherein R 1 CH 2 CH 3 .

14. The process according to claim 12 , wherein R 1 is CH 2 CH 3 .

15. The process according to claim 11 , wherein the compound according to formula I-a is obtained with a purity of at least 99% enantiomeric excess (e.e).

Assignments (2)
CHANGE OF NAME Recorded Jun 9, 2022
From: DEZIMA PHARMA B.V.
To: NEWAMSTERDAM PHARMA B.V.
Reel/Frame 060379/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2018
From: FORD, JOHN; GERARDUS SEERDEN, JOHANNES PAULUS; LEDRU, AMANDINE
To: DEZIMA PHARMA B.V.
Reel/Frame 046947/0130 →
Priority Claims (1)
NL PCT/NL2014/050556 · Aug 12, 2014 · national
Continuity (1)
Related Publication 20170267640A1 · Sep 21, 2017
Cited By (2)
US 12,378,221 US 12,570,628